ArticlePharmaceutics2023
Nanoemulsion Containing Kojic Dipalmitate and Rosehip Oil: A Promising Formulation to Treat Melasma.
Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 20 citations in OpenAlex.
- Kojic Acid as a Natural Hypopigmenting Agent: Biological Activities, Delivery Challenges, and Nanotechnology-Based Strategies.Pharmaceutics · 2026Review
- Kojic Acid Dipalmitate-Loaded Nanoparticles for the Treatment of Triple-Negative Breast Cancer.Journal of nanotechnology and nanomaterials · 2026Article
- Article
- DrEFO: A Fermented Oil Rich in Dihydroquercetin With High Antioxidant Activity.Journal of cosmetic dermatology · 2025Article
- Preparation and Evaluation of Nanoemulsion Formulation Containing Kojic Acid and Kojyl 3-aminopropylphosphonic Acid.Current pharmaceutical biotechnology · 2025Article
- Vegetable Oils in Skin Whitening - A Narrative Review.Current pharmaceutical design · 2025Review
- Energy-Based Methods and Nanocarrier-Based Approaches for Melasma Treatment.Advanced pharmaceutical bulletin · 2024Review
- Review
- Different therapeutic approaches in melasma: advances and limitations.Frontiers in pharmacology · 2024Review
- Unveiling the mechanisms for the development of rosehip-based dermatological products: an updated review.Frontiers in pharmacology · 2024Review
- Polymeric Nanocapsules Containing Ozonated Oil and Terbinafine Hydrochloride as a Potential Treatment Against Dermatophytes.AAPS PharmSciTech · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Melasma is a hard-to-treat hyperpigmentation disorder. Combined incorporation of kojic dipalmitate (KDP), the esterified form of kojic acid, and rosehip oil, an oil with antioxidant and skin-regenerating properties, into nanocarrier systems appears to be a suitable strategy to develop high-performance formulations. A high-energy method (Ultra-Turrax
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.